



Why was Marburg Virus given EUA status in December of 2020 when there have only been [413 deaths since 1967?](#)

Why was Marburg given EUA status when there are vaccines and treatment available?

June 28, 2022 – Sheila Hemphill’s Warning to Texas Senate Finance Committee, regarding

“The next pandemic: Marburg?”

[Bill Gates’ GAVI Article April 21, 2021](#)




“What was put in Emergency Use Authorization in December of 2020, was the Marburg Virus which is hemorrhagic, so the people going in having difficulty breathing with Coronavirus, envision them bleeding from their eyes and ears, cause it’s already in Emergency Use Authorization, they already have the vaccine and they already have the [PCR testing](#),”

Outbreaks can occur from vaccine distributions like [Spanish Flu](#) [Measles](#), etc.



Sabin Begins Marburg Vaccine Trial in U.S.

U.S. PHASE 2 CLINICAL TRIAL SITES



Washington, D.C. – April 16, 2025 – The Sabin Vaccine Institute has launched a multi-site Phase 2 clinical trial in the U.S. for its Marburg vaccine candidate, administering doses to the first participants in Melbourne, Florida. This trial builds on ongoing Phase 2 testing in Kenya and Uganda, with initial findings from that research expected in the coming months.

“Sudan Ebola and Marburg, right now there are no vaccines, there are no treatments.* And so Sabin is getting after that, we are developing the vaccines.” Norman Waters, Senior Director, R&D [Sabin Vaccine Institute](#). (MM 52 seconds)

[Marburg and Ebola](#) are [filoviruses](#) that cause hemorrhage, multiple organ failure, and high mortality rates. * By the end of 2019, both the United States and the European Union had approved the Ebola Zaire vaccine [rVSV-ZEBOV] that helped bring the epidemic to an end in June 2020. A second vaccine, the 2-dose vaccine known as Ad26.ZEBOV/MVA-BN-Filo.

African Journal of Infectious Diseases

DOWNLOAD PDF

OPEN ACCESS

DOI: [10.4314/ajid.v10i1.10](#)

Issue: [Vol. 10 No. 1 \(2016\)](#)

Rapid resolution of hemorrhagic fever (Ebola) in Sierra Leone with ozone therapy

Robert Jay Rowen
Howard Robins
Kojo Carew
Michael Morlai Kamara
Mohamed Ibrahim Jalloh

Conclusion: Ebola virus disease (EVD) may have a very narrow window of redox infectivity capacity, which can be easily exploited with Ozone Therapy (OT). OT may be a useful modality in EVD and other viral diseases and should be immediately studied to save lives that might otherwise be lost.

Results: Four symptomatic patients, three with test positive Ebola Virus Disease (EVD) confirmation and one (who suffered Ebola contaminated needle stick contamination three days earlier) without lab confirmation all remitted symptoms within 2-4 days and fully recovered. All four ill cases had an immediate recovery course upon initiation of therapy.

The single case of non-symptomatic high-risk exposure treated preventively did not develop symptoms.

([links](#) are live on website)